1. Home
  2. BLX vs ZYME Comparison

BLX vs ZYME Comparison

Compare BLX & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Latinoamericano de Comercio Exterior S.A.

BLX

Banco Latinoamericano de Comercio Exterior S.A.

HOLD

Current Price

$48.19

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$22.88

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLX
ZYME
Founded
1977
2003
Country
Panama
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1997
2022

Fundamental Metrics

Financial Performance
Metric
BLX
ZYME
Price
$48.19
$22.88
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$38.90
AVG Volume (30 Days)
108.3K
630.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
5.73%
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
$105,965,000.00
Revenue This Year
$13.11
$162.82
Revenue Next Year
$10.13
N/A
P/E Ratio
$8.26
N/A
Revenue Growth
N/A
38.87
52 Week Low
$31.14
$9.03
52 Week High
$51.99
$28.49

Technical Indicators

Market Signals
Indicator
BLX
ZYME
Relative Strength Index (RSI) 45.44 43.81
Support Level $43.50 $22.23
Resistance Level $51.60 $23.66
Average True Range (ATR) 1.12 1.42
MACD -0.33 -0.05
Stochastic Oscillator 33.62 9.06

Price Performance

Historical Comparison
BLX
ZYME

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: